NCT04122885 (IMMUNOPAC) is a clinical trial of PIPAC with oxaliplatin in Peritoneal Cancer, sponsored by University Hospital Tuebingen.

Who is sponsoring NCT04122885?

NCT04122885 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT04122885?

Interventions in NCT04122885: PIPAC with oxaliplatin, Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy.

What condition does NCT04122885 study?

NCT04122885 studies Peritoneal Cancer, Chemotherapy-Induced Change.

Is NCT04122885 still recruiting?

NCT04122885 is currently status unknown. Last updated 10 October 2019.

Last reviewed 2019-10-10 · How we verify

NCT04122885: IMMUNOPAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis

Status unknown Last updated 10 October 2019

What this trial tests

trial testing PIPAC with oxaliplatin in Peritoneal Cancer in 60 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
30 September 2020

30 September 2022

Quick facts

Lead sponsor	University Hospital Tuebingen
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 October 2019
Primary completion	30 September 2020
Estimated completion	30 September 2022
Sites	1 location across Germany

Drugs / interventions tested

PIPAC with oxaliplatin
Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy

Conditions studied

Peritoneal Cancer — all drugs for Peritoneal Cancer →
Chemotherapy-Induced Change — all drugs for Chemotherapy-Induced Change →

Sponsor

University Hospital Tuebingen

Who can join

18 and older, any sex, with Peritoneal Cancer or Chemotherapy-Induced Change. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The general goal of this study is to investigate the effect of treatment on serum concentrations of proteins known to impact angiogenesis or tumor growth and establishment in patients with peritoneal metastasis of various origin. Since the immune system is thought, by many, to have an impact on tumor growth and development, this study also seeks to determine the impact of abdominal surgery on postoperative immune function in PM patients, as judged by proteins known to influence immune function. This study will not only characterize the postoperative plasma but also to determine if the magnitude of any of the changes noted is associated with a worse or improved oncologic outcome. The principle purpose of this study is to gather perioperative serum/plasma samples from patients with PM from a variety of different primary tumors (ovarian, gastric, and colorectal) undergoing either CRS and HIPEC versus PIPAC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.
Harper MM, Kim J, Pandalai PK. · · 2022 · cited 14× · PMID 35628966 · DOI 10.3390/jcm11102840
Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma.
Bates AC, Klugh KL, Galaeva AO, Patch RA, et al · · 2025 · cited 2× · PMID 39940763 · DOI 10.3390/ijms26030994

Verify or expand the search:

Other recruiting trials for Peritoneal Cancer

Currently open trials in the same condition.

NCT06969833 — Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma · NA · recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
NCT06735326 — Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer · Phase 2 · recruiting
NCT07022535 — Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer · Phase 2 · recruiting
NCT06290193 — Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery · Phase 2 · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04122885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 10 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04122885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing